These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30693203)

  • 1. Left axillary active can positioning markedly reduces defibrillation threshold of a transvenous defibrillator failing to defibrillate at maximum output.
    Mitra RL
    HeartRhythm Case Rep; 2019 Jan; 5(1):36-39. PubMed ID: 30693203
    [No Abstract]   [Full Text] [Related]  

  • 2. Implantation of a unipolar cardioverter/defibrillator system under local anaesthesia.
    Stix G; Anvari A; Grabenwöger M; Merhaut C; Türel Z; Laufer G; Schmidinger H
    Eur Heart J; 1996 May; 17(5):764-8. PubMed ID: 8737108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Transvenous subcutaneous implantation technique of the cardioverter/defibrillator].
    Block M; Hammel D; Borggrefe M; Scheld HH; Breithardt G
    Herz; 1994 Oct; 19(5):259-77. PubMed ID: 8001899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ventricular Fibrillation Conversion Testing After Implantation of a Subcutaneous Implantable Cardioverter Defibrillator: Report From the National Cardiovascular Data Registry.
    Friedman DJ; Parzynski CS; Heist EK; Russo AM; Akar JG; Freeman JV; Curtis JP; Al-Khatib SM
    Circulation; 2018 Jun; 137(23):2463-2477. PubMed ID: 29463509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upper limit of vulnerability is a good estimator of shock strength associated with 90% probability of successful defibrillation in humans with transvenous implantable cardioverter-defibrillators.
    Swerdlow CD; Ahern T; Kass RM; Davie S; Mandel WJ; Chen PS
    J Am Coll Cardiol; 1996 Apr; 27(5):1112-8. PubMed ID: 8609329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous implantable cardioverter-defibrillator placement in a patient with a preexisting transvenous implantable cardioverter-defibrillator.
    Jazayeri MA; Emert MP; Bartos J; Tabbert T; Lakkireddy DR; Jazayeri MR
    HeartRhythm Case Rep; 2017 Jun; 3(6):306-310. PubMed ID: 28649503
    [No Abstract]   [Full Text] [Related]  

  • 7. Implantable intravascular defibrillator: defibrillation thresholds of an intravascular cardioverter-defibrillator compared with those of a conventional ICD in humans.
    Neuzil P; Reddy VY; Merkely B; Geller L; Molnar L; Bednarek J; Bartus K; Richey M; Bsee TJ; Sanders WE
    Heart Rhythm; 2014 Feb; 11(2):210-5. PubMed ID: 24144885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications.
    Orgeron GM; James CA; Te Riele A; Tichnell C; Murray B; Bhonsale A; Kamel IR; Zimmerman SL; Judge DP; Crosson J; Tandri H; Calkins H
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28588093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous implantable cardioverter-defibrillator: Initial experience.
    Galvão P; Cavaco D; Adragão P; Costa F; Carmo P; Morgado F; Bernardo R; Nunes M; Abecasis M; Neves J; Mendes M
    Rev Port Cardiol; 2014 Sep; 33(9):511-7. PubMed ID: 25242675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated defibrillation threshold when right-sided venous access is used for nonthoracotomy implantable defibrillator lead implantation. The Endotak Investigators.
    Epstein AE; Kay GN; Plumb VJ; Voshage-Stahl L; Hull ML
    J Cardiovasc Electrophysiol; 1995 Nov; 6(11):979-86. PubMed ID: 8589875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Saga of Defibrillation Testing: When Less Is More.
    Gleva MJ; Robinson M; Poole J
    Curr Cardiol Rep; 2018 May; 20(6):44. PubMed ID: 29730796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.
    Klein HU; Goldenberg I; Moss AJ
    Eur Heart J; 2013 Aug; 34(29):2230-42. PubMed ID: 23729691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of defibrillation testing on management during implantable cardioverter-defibrillator implantation.
    Leong-Sit P; Gula LJ; Diamantouros P; Krahn AD; Skanes AC; Yee R; Klein GJ
    Am Heart J; 2006 Dec; 152(6):1104-8. PubMed ID: 17161062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defibrillators: Selecting the Right Device for the Right Patient.
    Al-Khatib SM; Friedman P; Ellenbogen KA
    Circulation; 2016 Nov; 134(18):1390-1404. PubMed ID: 27799257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defibrillation testing in everyday medical practice during implantable cardioverter defibrillator implantation in France: analysis from the LEADER registry.
    Sadoul N; Defaye P; Mouton E; Bizeau O; Dupuis JM; Blangy H; Delarche N; Blanc JJ; Lazarus A;
    Arch Cardiovasc Dis; 2013 Nov; 106(11):562-9. PubMed ID: 24200925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable transvenous cardioverter-defibrillators.
    Bardy GH; Hofer B; Johnson G; Kudenchuk PJ; Poole JE; Dolack GL; Gleva M; Mitchell R; Kelso D
    Circulation; 1993 Apr; 87(4):1152-68. PubMed ID: 8462144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative technique for implanting an epicardial cardioverter defibrillation patch during a tricuspid valve replacement for arrhythmogenic right ventricular cardiomyopathy.
    Yoda M; Tanabe H; Kishi M; Suma H
    Interact Cardiovasc Thorac Surg; 2011 Apr; 12(4):628-30. PubMed ID: 21220415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of defibrillation threshold testing during implantable cardioverter-defibrillator placement: data from the Israeli ICD Registry.
    Arnson Y; Suleiman M; Glikson M; Sela R; Geist M; Amit G; Schliamser JE; Goldenberg I; Ben-Zvi S; Orvin K; Rosenheck S; Adam Freedberg N; Strasberg B; Haim M
    Heart Rhythm; 2014 May; 11(5):814-21. PubMed ID: 24486799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment with an implantable cardioverter defibrillator for spontaneous ventricular fibrillation in dilated cardiomyopathy with very high defibrillation thresholds.
    Tamura K; Abe H; Nagatomo T; Nakashima Y
    J UOEH; 2001 Dec; 23(4):363-8. PubMed ID: 11789138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.